Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: SCFβ-TRCP suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2.

The Journal of experimental medicine·2025
Same author

Antiangiogenic Variant of TSP-1 Targets Tumor Cells in Glioblastomas.

Molecular therapy : the journal of the American Society of Gene Therapy·2024
Same author

Antiangiogenic Variant of TSP-1 Targets Tumor Cells in Glioblastomas.

Molecular therapy : the journal of the American Society of Gene Therapy·2024
Same author

Bio-based adsorption foam composed of MOF and polyethyleneimine-modified cellulose for selective anionic dye removal.

Environmental research·2024
Same author

Genetic architecture and genomic prediction of plant height-related traits in chrysanthemum.

Horticulture research·2024
Same author

Targeting pyroptosis with nanoparticles to alleviate neuroinflammatory for preventing secondary damage following traumatic brain injury.

Science advances·2024

Related Experiment Video

Updated: Jul 14, 2026

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Thrombospondin-based antiangiogenic therapy.

Xuefeng Zhang1, Jack Lawler

  • 1Department of Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA.

Microvascular Research
|June 15, 2007
PubMed
Summary

Thrombospondins (TSPs), particularly TSP-1 and TSP-2, are key inhibitors of angiogenesis. Research explores their therapeutic potential in antiangiogenic therapies by understanding their mechanisms and optimizing delivery strategies.

More Related Videos

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia
07:48

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia

Published on: June 8, 2019

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles
09:01

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles

Published on: September 27, 2013

Related Experiment Videos

Last Updated: Jul 14, 2026

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia
07:48

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia

Published on: June 8, 2019

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles
09:01

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles

Published on: September 27, 2013

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Background:

  • Thrombospondins (TSPs) are extracellular matrix proteins crucial for tissue development and repair.
  • TSP-1 and TSP-2 are potent endogenous inhibitors of angiogenesis, a process vital for both normal tissue development and pathological conditions like cancer.
  • Their antiangiogenic properties stem from direct effects on vascular endothelial cells and indirect modulation of angiogenic regulators.

Purpose of the Study:

  • To review the progress in thrombospondin-based antiangiogenic therapy.
  • To discuss the mechanisms of action for TSP-1 and TSP-2 in inhibiting angiogenesis.
  • To explore therapeutic strategies for optimizing TSP activities.

Main Methods:

  • Review of experimental models demonstrating TSP-1 and TSP-2 antiangiogenic effects.
  • Analysis of mechanisms involving direct and indirect actions on angiogenic processes.
  • Evaluation of therapeutic approaches including endogenous TSP up-regulation and recombinant protein/peptide delivery.

Main Results:

  • TSP-1 and TSP-2 exhibit significant inhibitory effects on angiogenesis through diverse mechanisms.
  • Understanding these mechanisms facilitates the design of targeted antiangiogenic therapies.
  • Therapeutic strategies involve enhancing endogenous TSPs or administering TSP-derived molecules.

Conclusions:

  • Thrombospondin-based therapies hold promise for antiangiogenic treatment.
  • Further research is needed to overcome challenges in optimizing these therapeutic strategies.
  • Continued investigation into TSP mechanisms will refine future antiangiogenic drug development.